Takeda Pharmaceutical (NYSE:TAK) Cut to “Hold” at Wall Street Zen

Takeda Pharmaceutical (NYSE:TAK) was downgraded by research analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research report issued on Monday.

TAK has been the topic of a number of other reports. Zacks Research lowered shares of Takeda Pharmaceutical from a “hold” rating to a “strong sell” rating in a research note on Monday, June 29th. Weiss Ratings downgraded shares of Takeda Pharmaceutical from a “hold (c)” rating to a “hold (c-)” rating in a research note on Tuesday, June 23rd. Finally, Sanford C. Bernstein raised shares of Takeda Pharmaceutical from a “market perform” rating to an “outperform” rating in a research note on Wednesday, April 8th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold”.

Takeda Pharmaceutical Stock Performance

TAK opened at $16.73 on Monday. The firm has a fifty day moving average price of $16.09 and a 200 day moving average price of $16.87. The stock has a market cap of $53.26 billion, a P/E ratio of 42.91 and a beta of -0.07. Takeda Pharmaceutical has a 1 year low of $12.99 and a 1 year high of $18.90. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.09 and a quick ratio of 0.60.

Takeda Pharmaceutical (NYSE:TAK) last posted its earnings results on Tuesday, March 31st. The company reported $0.56 earnings per share (EPS) for the quarter. The business had revenue of $6.90 billion for the quarter. Takeda Pharmaceutical had a net margin of 4.31% and a return on equity of 11.20%. Equities research analysts anticipate that Takeda Pharmaceutical will post 0.94 earnings per share for the current year.

Hedge Funds Weigh In On Takeda Pharmaceutical

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Valeo Financial Advisors LLC grew its holdings in Takeda Pharmaceutical by 6.0% in the 4th quarter. Valeo Financial Advisors LLC now owns 11,220 shares of the company’s stock valued at $175,000 after buying an additional 632 shares in the last quarter. Franklin Resources Inc. raised its holdings in shares of Takeda Pharmaceutical by 3.8% during the 3rd quarter. Franklin Resources Inc. now owns 19,458 shares of the company’s stock worth $285,000 after acquiring an additional 713 shares during the period. Abel Hall LLC raised its holdings in shares of Takeda Pharmaceutical by 2.3% during the 1st quarter. Abel Hall LLC now owns 34,099 shares of the company’s stock worth $632,000 after acquiring an additional 781 shares during the period. Private Trust Co. NA boosted its position in shares of Takeda Pharmaceutical by 84.7% during the 4th quarter. Private Trust Co. NA now owns 1,707 shares of the company’s stock valued at $27,000 after acquiring an additional 783 shares during the last quarter. Finally, Checchi Capital Advisers LLC boosted its position in shares of Takeda Pharmaceutical by 5.7% during the 1st quarter. Checchi Capital Advisers LLC now owns 14,591 shares of the company’s stock valued at $270,000 after acquiring an additional 786 shares during the last quarter. Institutional investors and hedge funds own 9.17% of the company’s stock.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.